Drug Trial Radar · NCT07288580
A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations
Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Apr 2, 2026
Primary completion
Jun 30, 2028
Study completion Dec 30, 2033
Sponsor
- Lead sponsor
- Shanghai Euhearing Therapeutics Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, single-arm, open-label Phase I/II clinical trial, which is designed to evaluate the safety, tolerability and efficacy of EHT102 injection in treating congenital hearing loss secondary to biallelic mutations of OTOF (DFNB9).Up to 30 pediatric participants (A maximum of 15 participants will be enrolled in each of the United States and China) will be enrolled and dosed with EHT102. The dose-escalation phase (Phase I) includes two predefined dose cohorts (3 participants per cohort), with sequential enrollment from low to high dose. During dose escalation, each participant will receive a unilateral EHT102 injection followed by safety observation.
Conditions
- Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Interventions
EHT102 InjectionDrug
EHT102 injection is a dual-vector gene therapy product developed for the treatment of OTOF-related hearing loss.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Related Adverse Events as Assessed by CTCAE v5.0Time frame: Up to week 52
- Proportion of Participants Achieving a Hearing Sensitivity Threshold of ≤70 dB by behavioral audiometryTime frame: Up to week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eye & ENT Hospital of Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.